Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
$26.5M Sell
945,042
-215,834
-19% -$6.06M 0.02% 783
2014
Q2
$32.7M Buy
1,160,876
+174,016
+18% +$4.96M 0.03% 636
2014
Q1
$30.1M Buy
986,860
+579,594
+142% +$17.3M 0.03% 602
2013
Q4
$11.8M Buy
407,266
+261,287
+179% +$7.6M 0.01% 1132
2013
Q3
$3.98M Sell
145,979
-3,813,161
-96% -$104M ﹤0.01% 1918
2013
Q2
$105M Buy
+3,959,140
New +$109M 0.12% 174

Other funds holding PFE

UBS's PFE Position: Q3 2014 in Review

UBS increased its Pfizer (PFE) stake by 8.4% in Q3 2014, buying an estimated $41.1M and bringing the position to 18,946,615 shares worth $532M. The position accounts for 0.39% of the portfolio, ranked #35.

UBS first reported a position in PFE in Q2 2013 and has held it in 6 quarters since. 1,742 funds tracked by Wall St. Rank hold PFE as of Q3 2014.

  • UBS held 18,946,615 shares of Pfizer worth $532M as of Q3 2014.
  • UBS bought 1,464,015 Pfizer shares in Q3 2014, an estimated $41.1M.
  • Pfizer made up 0.39% of UBS's portfolio in Q3 2014, its #35 holding.
  • UBS first reported a position in Pfizer in Q2 2013 and has held it in 6 quarters since.
  • 1,742 funds tracked by Wall St. Rank held Pfizer as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.